Fmr Llc Sells 290,912 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) Stock

Sana Biotechnology, Inc. (NASDAQ:SANA) insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Sana Biotechnology Price Performance

Shares of SANA opened at $3.66 on Friday. The firm has a 50-day simple moving average of $2.40 and a two-hundred day simple moving average of $4.06. Sana Biotechnology, Inc. has a 1-year low of $1.52 and a 1-year high of $12.00. The stock has a market cap of $817.16 million, a PE ratio of -2.61 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. As a group, sell-side analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on SANA shares. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, HC Wainwright lifted their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Sana Biotechnology by 17.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock valued at $146,000 after acquiring an additional 5,338 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Sana Biotechnology by 2.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock valued at $1,056,000 after purchasing an additional 6,823 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Sana Biotechnology in the third quarter valued at approximately $29,000. Arizona State Retirement System grew its holdings in shares of Sana Biotechnology by 36.7% in the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after purchasing an additional 9,940 shares in the last quarter. Finally, Stifel Financial Corp purchased a new stake in Sana Biotechnology during the 3rd quarter worth approximately $43,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.